Scheelevägen 19 A
120 articles with Alligator Bioscience
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.
It was a particularly busy week for clinical trial announcements. Let's take a look.
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
Alligator Bioscience announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB targeting drug candidate, ATOR-1017.
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Alligator Bioscience announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab.
During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs.
Alligator Bioscience Alligator Bioscience, announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer.
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
Alligator Bioscience announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OPTIMIZE-1 study with the University of Pennsylvania's Pancreatic Cancer Research Center.
Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
Alligator Bioscience announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset, mitazalimab.
Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data
Alligator Bioscience announced an update on the on-going clinical Phase I trial with the 4-1BB drug candidate ATOR-1017, which is developed as a tumor-directed therapy for metastatic cancer.
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting bispecific antibodies.
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
Alligator Bioscience AB today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies.
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
Alligator Bioscience AB and Aptevo Therapeutics announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society of Immunotherapy Cancer's 36th Annual Meeting, taking place virtually and in-person November 12- 14, 2021 in Washington D.C.
Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam
First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer.
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 8 November 2021.
Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
Alligator Bioscience AB and Scandion Oncology A/S, announced the conclusion of their collaboration with a very positive outcome.
Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Alligator Bioscience AB announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity.
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
Alligator Bioscience announced that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics
Alligator Bioscience today announced that Julie Silber has joined the company as the new Senior Director of Communications and Investor Relations.